Literature DB >> 11864573

The p21-activated kinase PAK is negatively regulated by POPX1 and POPX2, a pair of serine/threonine phosphatases of the PP2C family.

Cheng-Gee Koh1, E-Jean Tan, Edward Manser, Louis Lim.   

Abstract

The Rho GTPases are involved in many signaling pathways and cellular functions, including the organization of the actin cytoskeleton, regulation of transcription, cell motility, and cell division. The p21 (Cdc42/Rac)-activated kinase PAK mediates a number of biological effects downstream of these Rho GTPases (reviewed by [1]). The phosphorylation state of mammalian PAK is highly regulated: upon binding of GTPases, PAK is potently activated by autophosphorylation at multiple sites, although the mechanisms of PAK downregulation are not known. We now report two PP2C-like serine/threonine phosphatases (POPX1 and POPX2) that efficiently inactivate PAK. POPX1 was isolated as a binding partner for the PAK interacting guanine nucleotide exchange factor PIX. The dephosphorylating activity of POPX correlates with an ability to block the in vivo effects of active PAK. Consonant with these effects on PAK, POPX can also inhibit actin stress fiber breakdown and morphological changes driven by active Cdc42(V12). The association of the POPX phosphatases with PAK complexes may allow PAK to cycle rapidly between active and inactive states; it represents a unique regulatory component of the signaling pathways of the PAK kinase family.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864573     DOI: 10.1016/s0960-9822(02)00652-8

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  44 in total

1.  MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.

Authors:  Sarah Jurmeister; Marek Baumann; Aleksandra Balwierz; Ioanna Keklikoglou; Aoife Ward; Stefan Uhlmann; Jitao David Zhang; Stefan Wiemann; Özgür Sahin
Journal:  Mol Cell Biol       Date:  2011-12-05       Impact factor: 4.272

Review 2.  The role of serine/threonine protein phosphatases in exocytosis.

Authors:  Alistair T R Sim; Monique L Baldwin; John A P Rostas; Jeff Holst; Russell I Ludowyke
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

3.  GIT1 activates p21-activated kinase through a mechanism independent of p21 binding.

Authors:  Tsui-Han Loo; Yuen-Wai Ng; Louis Lim; Ed Manser
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

4.  Constitutive p21-activated kinase (PAK) activation in breast cancer cells as a result of mislocalization of PAK to focal adhesions.

Authors:  Mary R Stofega; Luraynne C Sanders; Elisabeth M Gardiner; Gary M Bokoch
Journal:  Mol Biol Cell       Date:  2004-03-26       Impact factor: 4.138

Review 5.  PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation.

Authors:  Zhou-shen Zhao; Ed Manser
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

Review 6.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

7.  Evolution of the metazoan protein phosphatase 2C superfamily.

Authors:  Adi Stern; Eyal Privman; Michal Rasis; Sara Lavi; Tal Pupko
Journal:  J Mol Evol       Date:  2006-12-06       Impact factor: 2.395

8.  Nbp2 targets the Ptc1-type 2C Ser/Thr phosphatase to the HOG MAPK pathway.

Authors:  James Mapes; Irene M Ota
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

Review 9.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

Review 10.  Negative regulation of multifunctional Ca2+/calmodulin-dependent protein kinases: physiological and pharmacological significance of protein phosphatases.

Authors:  A Ishida; N Sueyoshi; Y Shigeri; I Kameshita
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.